Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche steps up Tamiflu distribution
States that have seen a particularly high increase in flu incidence recently include California, Arizona, New Mexico, Utah, Texas, Oregon, Nevada and Kansas. Under the company’s plan, Tamiflu
States that have seen a particularly high increase in flu incidence recently include California, Arizona, New Mexico, Utah, Texas, Oregon, Nevada and Kansas. Under the company’s plan, Tamiflu
The research could open up pathways for the development of treatments for multiple sclerosis (MS) and other such neuro-inflammatory disorders. The researchers reported experiments showing how the endocannabinoid
Roche and Xencor entered into the initial collaboration in January 2005, in which Roche applies Xencor’s XmAb Fc domains with the aim of enhancing the therapeutic efficacy of
The study compares Natrecor with placebo in order to gauge the risk profile of the drug. The new findings may exacerbate recent safety concerns around the drug, which
This follows a similar approval for a phase I/II trial for ZIO-201 in patients with advanced sarcoma. Patient treatment in both trials is expected to start in early
Under the terms of the agreement, Pfizer will fund further research at Sangamo and Sangamo will use its zinc finger DNA-binding protein (ZFP) technology to develop additional cell
The approval means that Climara Pro is the only combination once-a-week hormone therapy patch approved for the prevention of postmenopausal osteoporosis and the relief of vasomotor symptoms associated
Paroxysmal nocturnal hemoglobinuria (PNS) is a rare form of hemolytic anemia characterized by destruction of red blood cells by the immune system. In accordance with the trial (TRIUMPH)’s
If the company gets approval from the FDA, the third-party manufacturing facility will offer increased production capacity for the drug. The FDA approved Orencia, the first selective modulator
The new designation comes after the company presented positive results from a phase I/II study of the drug in May 2005. This fast track designation gives Genmab the